Stenoparib's Phase 2 readout in platinum-resistant ovarian cancer will determine whether DRP-guided patient selection can unlock a viable path to pivotal approval

Bull

A positive readout would show objective response rates and/or durable disease control in DRP-selected platinum-resistant patients that meaningfully exceed historical benchmarks for this heavily pretreated population (ORR typically 10-20% for single-agent chemotherapy), with the extended overall survival and 30+ month durability signals from the AACR presentation extending into the amended protocol cohort. This would validate DRP as a genuine patient-selection tool, de-risk the pivotal trial design, and position stenoparib as a differentiated PARP inhibitor in a setting where approved PARP inhibitors have limited utility due to platinum resistance and HRD enrichment requirements.

Bear

The most likely failure modes are insufficient efficacy in the platinum-resistant cohort despite DRP selection — either low ORR or short duration of response that does not differentiate stenoparib from available salvage options — or DRP failing to adequately enrich for responders, undermining the entire biomarker-driven strategy. Tolerability issues at the optimized dose, or a patient population too heterogeneous to generate a clean signal, could also produce an inconclusive dataset that neither supports nor clearly refutes advancement to a pivotal study.